|
| Status |
Public on Oct 23, 2014 |
| Title |
Combination P1P-2 |
| Sample type |
RNA |
| |
|
| Source name |
prostate tumor_OMN54+Docetaxel
|
| Organism |
Homo sapiens |
| Characteristics |
host strain: NOD-SCID mice
host strain gender: male
cell line source: LTL-313H
tissue type: patient-derived prostate cancer tissue xenograft
treated with: OMN54 + Docetaxel in combination
|
| Treatment protocol |
After about 6 weeks, when levels of ~12 ng PSA/ml plasma had been reached, i.e. equivalent to tumor volumes of 30-50 mm^3, the mice were randomly distributed into 6 groups and treated with docetaxel (ip; Q7d/3) and Aneustat (orally; Q1dX5/3) along the following schedule: (a) vehicle control, (b) docetaxel (5 mg/kg), (c) Aneustat (1652 mg/kg), (d) docetaxel (5 mg/kg) + Aneustat (413 mg/kg), (e) docetaxel (5 mg/kg) + Aneustat (826 mg/kg), and (f) docetaxel (5 mg/kg) + Aneustat (1652 mg/kg). Expression microarray data were obtained from LTL-313H xenografts treated under four different conditions: docetaxel (5 mg/kg), Aneustat (1652 mg/kg), docetaxel (5 mg/kg) + Aneustat (1652 mg/kg), and untreated controls. Aneustat and docetaxel were both dissolved in DMSO and added as single drugs or in various combinations. DMSO was used as the vehicle control.
|
| Growth protocol |
The LTL-313H transplantable, PTEN-deficient, metastatic and PSA-secreting, patient-derived prostate cancer tissue line (generation 13) was maintained as grafts under renal capsules of male NOD-SCID mice supplemented with testosterone as described in manuscript. For experiments, tumors were harvested 10 weeks after grafting and pieces of tumor tissue (2.5x2.5x1.25 mm3) were grafted under the renal capsules of 36 testosterone-supplemented male mice (6 groups; 6 mice/group; 4 grafts/mouse). The grafts had a 100% engraftment rate with an average tumor volume doubling time of 13-15 days. Increases in the plasma PSA levels of the mice were used as a measure of tumor growth.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was extracted from xenograft tissues using a mirVana™ miRNA Isolation Kit (Life Technologies, Burlington, ON, Canada) according to the manufacturer's instructions.
|
| Label |
Cy3
|
| Label protocol |
100ng of total RNA was used as input for generation of Cyanine-3-labeled cRNA following Agilent’s One-Color Microarray-Based Gene Expression Analysis Low Input Quick Amp Labeling v6.0.
|
| |
|
| Hybridization protocol |
600ng labeled cRNA was hybridized on Agilent SurePrint G3 Human GE 8x60K Microarray (Design ID 028004)
|
| Scan protocol |
Slides were scanned with the Agilent DNA Microarray Scanner at a 3um scan resolution using the one colour and 20 bit tiff file settings
|
| Data processing |
Image files were processed with Agilent Feature Extraction 11.0.1.1 to produce spatially detrended and background subtracted gProcessedSignal intensities. Processed green signal was quantile normalized with Agilent GeneSpring 12.0.
|
| |
|
| Submission date |
Jul 10, 2013 |
| Last update date |
Apr 23, 2018 |
| Contact name |
Shawn Anderson |
| E-mail(s) |
Sanderson@prostatecentre.com
|
| Organization name |
Vancouver Prostate Centre
|
| Lab |
Laboratory for Advanced Genome Analysis
|
| Street address |
2660 Oak Street
|
| City |
Vancouver |
| State/province |
BC |
| ZIP/Postal code |
V6H3Z6 |
| Country |
Canada |
| |
|
| Platform ID |
GPL17077 |
| Series (1) |
| GSE48667 |
Enhancement by Aneustat (OMN54) of docetaxel anticancer activity in a patient-derived prostate cancer tissue xenograft model |
|
| Relations |
| Reanalyzed by |
GSE113533 |
